查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1479910

血流动力学监测系统市场－2024年至2029年预测

Hemodynamic Monitoring Systems Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 126 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

2022 年血液动力学监测系统市场的市场规模为 942,753,000 美元，预计在预测期内复合年增长率为 6.01%，到 2029 年达到 1,418,612,000 美元的市场规模。

血流动力学监测系统直接测量静脉、心臟和动脉的血压。它还会检查您的血流量和氧气水平。这些系统还包括用于记录诊断导管插入、冠状动脉、週边和电生理学 (EP) 操作的介面。

微创技术支援连续监测每搏输出量并提供动态液体反应性资讯。有些系统测量容量预载係数，而有些系统则使用专有导管连续监测中心静脉饱和度。

血流动力学监测系统的技术进步、血流动力学监测系统研究的增加、创业投资资金的流入、心血管疾病和糖尿病盛行率的上升、老年人口的增长以及手术量的增加、行业意识提升的努力和政府推动了成长。

市场驱动因素

  • 技术进步

近年来，侵入性技术已不再普及，人们越来越倾向于非侵入性选择。非侵入性血流动力学监测技术可以实现无痛诊断，并限制患者感染血液传染疾病的可能性。此外，与侵入性系统相比，这些系统侵入性较小，可以在没有专家或医生的情况下由护士操作。

这一优势可同时监测多个患者的血流动力学，从而减少人员配备和治疗成本。由于这些优势，非侵入式系统的市场在未来几年可能会成长。对于重症患者，非侵入性血流动力学监测需要用指套连续测量血压，并用脉搏轮廓技术测量心抟出量。例如，Caretaker Medical 的 Caretaker 4 使用指套测量连续脉动血压 (“cNIBP”)、心率和其他生理资料。

  • 心血管疾病增加

该市场主要受到心臟衰竭、冠状动脉疾病和心律不整等慢性心血管疾病 (CVD) 盛行率不断上升的推动。这些病理需要持续监测血流动力学参数，以确保有效的诊断、治疗和管理。

根据《世界心臟报告》，心血管疾病影响全球超过 5 亿人，到 2021 年将导致 2,050 万人死亡。不健康的饮食、缺乏体力活动、吸烟和有害的饮酒已被确定为心臟病和中风最重要的行为危险因素。

老年人口不断增加、不健康的生活方式和肥胖率上升等因素进一步加剧了心血管疾病的负担。总的来说，这些因素导致对血流动力学监测的需求不断增加，血流动力学监测是应对心血管疾病带来的挑战的基本要素。

市场限制：

  • 与侵入性血流动力学监测市场相关的风险。

除了侵入性监测（特别是插入肺动脉导管）带来的不适之外，该手术还存在多种风险：败血症、出血、心律不整、四肢远端血液循环减少、出血、神经损伤（插入期间）。血栓症、空气栓塞、肺毛细血管坏死。

这些因素会增加侵入性血流动力学手术期间的死亡率。因此，侵入性血流动力学监测仅提案用于有限的目的，假设在手术过程中获取相关资料的好处超过了风险。

此外，不建议老年或体弱患者使用侵入性血流动力学监测方法。此外，侵入式血流动力学监测非常昂贵且需要由合格的专业人员将导管放置在患者体内。儘管有创血流动力学监测可以提供有关患者血流动力学状态的准确、全面和连续的资料，但其使用受到上述风险的限制。

血流动力学监测系统市场按类型分为非侵入性、微创和侵入。

血流动力学监测系统市场分为非侵入性法、微创法和侵入法等类型。非侵入性监测适用于医院病房、急诊室、居家医疗等多种环境下的连续监测。

微创系统用于病情较严重的患者，例如在加护病房或某些医疗程序期间。侵入性监测仅限于重症患者，并在必要时包括高度准确和详细的血流动力学测量。

预计北美将占据血流动力学监测市场的主要份额。

北美是血流动力学监测市场的重要地区，在未来几年仍将如此。由于知名市场参与企业的存在、技术先进的医院的存在以及该地区医院接受治疗的重症患者数量不断增加，血流动力学监测市场预计将发展最快。

由于 FDA 对监测设备的核准增加和新产品的发布，北美血流动力学监测市场在预测期内可能会扩大。

市场开拓：

  • 2023 年 7 月 - Retia Medical 宣布天普大学收购其 Argos 血流动力学监测仪。此次收购对于 Retia Medical 来说是一个显着的里程碑，巩固了该公司在学术和研究界的地位。
  • 2023年6月－迈瑞医疗与欧洲Edwards Lifesciences合作推出先进的血流动力学监测解决方案。这是两家公司策略伙伴关係的一个重要里程碑。 Edwards Lifesciences 与迈瑞医疗 (Mindray Medical) 合作，迈瑞医疗是结构性心臟病和重症加护监测领域医疗创新的全球领导者，也是医疗设备和解决方案的领先提供者。
  • 2022 年 6 月 - 着名的高清无线超音波系统供应商 Clarius 行动医疗和血流动力学超音波专家ImaCor 宣布推出世界上首个手持式经食道超音波心动图(TEE) 系统，并宣布建立合作伙伴关係以推广。这款突破性系统专为加护病房（ICU）重症患者的管理和护理指导而设计。这项突破性系统已获得美国食品药物管理局(FDA) 的批准，使临床医生能够做出更快、更准确和明智的决策，从而帮助改善 ICU患者照护。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现
  • 分析师观点

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章血流动力学监测系统市场：依类型

  • 介绍
  • 非侵入性
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 微创
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 侵入性的
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第六章血流动力学监测系统市场：副产品

  • 介绍
  • 监视器
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 一次性的
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第七章血流动力学监测系统市场：依最终用户分类

  • 介绍
  • 医院/诊所
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 门诊治疗中心
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 居家照护设置
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第八章血流动力学监测系统市场：按地区

  • 介绍
  • 北美洲
    • 按类型
    • 副产品
    • 按最终用户
    • 按国家/地区
  • 南美洲
    • 按类型
    • 副产品
    • 按最终用户
    • 按国家/地区
  • 欧洲
    • 按类型
    • 副产品
    • 按最终用户
    • 按国家/地区
  • 中东/非洲
    • 按类型
    • 副产品
    • 按最终用户
    • 按国家/地区
  • 亚太地区
    • 按类型
    • 副产品
    • 按最终用户
    • 按国家/地区

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十章 公司简介

  • Edward Lifesciences Corporation
  • GE Healthcare
  • Koninklijke Philips NV
  • Draeger
  • LiDCO Group PLC
  • Pulsion Medical Systems SE
  • ICU Medical, Inc.
  • Cheetah Medical, Inc.
  • CNSystems Medizintechnik GmbH
  • Schwarzer Cardiotek GmbH
简介目录
Product Code: KSI061611466

Hemodynamic Monitoring Systems Market was valued at US$942.753 million in 2022 and is expected to grow at a CAGR of 6.01% over the forecast period to reach a market size of US$1418.612 million by 2029.

Hemodynamic monitoring systems take blood pressure readings directly from the veins, heart, and arteries. They also check for blood flow and oxygen levels. These systems also include interfaces for recording diagnostic catheterizations, and coronary, peripheral, and electrophysiology (EP) operations.

The minimally invasive technologies aid in the continuous monitoring of stroke volume and provide dynamic fluid responsiveness information. Some of the systems measure volumetric preload factors, while others use proprietary catheters to continuously monitor central venous saturation.

The growth is being driven by technological advancements in hemodynamic monitoring systems, increased research into hemodynamic monitoring systems, an influx of venture capital funding, a rising prevalence of cardiovascular diseases and diabetes, a rising geriatric population & growing number of surgeries, industry awareness initiatives, and government focus on critical care infrastructure & services.

Market Drivers:

  • Technological advancements-

With an increasing preference for noninvasive alternatives, Invasive techniques have become less popular in recent years. Noninvasive hemodynamic monitoring technologies allow for painless diagnosis and limit the chance of patients contracting blood-borne diseases. Furthermore, these systems are less invasive and can be operated by a nurse in the absence of a professional or doctor as opposed to invasive systems.

Due to this advantage, the hemodynamic status of multiple patients can be monitored at the same time, resulting in lower staffing and treatment costs. The market for non-invasive systems is likely to grow in the next years due to these benefits. For critically ill patients, noninvasive hemodynamic monitoring requires continuous measurement of blood pressure with finger cuffs and measurement of cardiac output with the pulse contour method. The Caretaker 4 from Caretaker Medical, for example, measures continuous beat-by-beat blood pressure ("cNIBP"), heart rate, and other physiological data with a finger cuff.

  • Growing cardiovascular diseases-

The market is driven significantly by the increasing prevalence of chronic cardiovascular diseases (CVDs) such as heart failure, coronary artery disease, and arrhythmias. These medical conditions necessitate continuous monitoring of hemodynamic parameters to ensure effective diagnosis, treatment, and management.

According to the World Heart Report, more than half a billion people worldwide are affected by cardiovascular diseases, resulting in 20.5 million deaths in 2021. An unhealthy diet, physical inactivity, tobacco use, and harmful alcohol consumption are identified as the most critical behavioral risk factors for heart disease and stroke.

The rising burden of CVDs is further exacerbated by factors such as a growing geriatric population, unhealthy lifestyles, and increasing rates of obesity. These factors collectively contribute to an escalating demand for hemodynamic monitoring as an essential component in addressing the challenges posed by cardiovascular diseases.

Market Restraint:

  • Risks involved with invasive hemodynamic monitoring market-

Apart from the discomfort of invasive monitoring (particularly the insertion of the pulmonary artery catheter), there are several risks associated with this procedure: sepsis, bleeding, cardiac arrhythmias, reduced circulation to the distal limb, hemorrhage, nerve damage (during insertion), thrombosis, air embolism, and pulmonary capillary necrosis.

During invasive hemodynamic procedures, these factors increase the fatality rate. Hence, invasive hemodynamic monitoring is only suggested for a limited number of purposes, assuming that the risks are outweighed by the benefits of obtaining relevant data during the procedure.

Furthermore, invasive hemodynamic monitoring methods are not advised for elderly or weak patients. Furthermore, invasive hemodynamic monitoring is very costly and necessitates the use of qualified professionals to place catheters in patients. Even though invasive hemodynamic monitoring gives accurate, comprehensive, and continuous data regarding a patient's hemodynamic state, the risks described above limit its use.

The hemodynamic monitoring systems market is segmented by type into non-invasive, minimally invasive, and invasive

The market for hemodynamic monitoring systems is categorized by type, including non-invasive, minimally invasive, and invasive methods. Non-invasive monitoring is well-suited for continuous monitoring across diverse settings, such as hospital wards, emergency departments, and home care.

Minimally invasive systems are employed for more critically ill patients, typically in intensive care units and during specific medical procedures. Invasive monitoring is reserved for critically ill patients, providing highly accurate and detailed hemodynamic measurements when required.

North America is anticipated to hold a significant share of the hemodynamic monitoring market-

North America is a significant region in the hemodynamic monitoring market and is likely to do so for a few more years. Due to the existence of prominent market participants, technologically advanced hospitals, and an increasing number of critically ill patients being treated in hospitals throughout the region, the hemodynamic monitoring market is expected to develop the most.

The North American hemodynamic monitoring market is likely to increase during the forecast period, thanks to rising FDA approvals for monitoring devices and new product releases.

Market Developments:

  • July 2023- Retia Medical announced the acquisition of its Argos hemodynamic monitor by Temple University. This acquisition marked a noteworthy milestone for Retia Medical, solidifying its presence in the academic and research communities. The expert medical professionals and researchers at Temple University gained access to the advanced Hemodynamic Monitoring capabilities of the Argos monitor, contributing to the enhancement of patient care.
  • June 2023- Mindray Medical announced the launch of an advanced hemodynamic monitoring solution in collaboration with Edwards Lifesciences in Europe. This marked a significant milestone in their strategic cooperation agreement. Edwards Lifesciences, a global leader in medical innovations for structural heart disease and critical care monitoring, collaborated with Mindray Medical, a leading medical device and solution provider. The milestone involved integrating the Edwards FloTracTM sensor for hemodynamic monitoring into Mindray's flagship BeneVision N series patient monitors.
  • June 2022- Clarius Mobile Health, a prominent provider of high-definition wireless ultrasound systems, and ImaCor Inc., a company specializing in hemodynamic ultrasound, announced a partnership that facilitated the introduction of the world's first handheld transesophageal echocardiography (TEE) system. This innovative system was specifically designed for managing and guiding care for critically ill patients in the Intensive Care Unit (ICU). This groundbreaking system received clearance from the U.S. Food and Drug Administration (FDA), empowering clinicians to make informed decisions promptly and accurately, thereby enhancing patient care in the ICU.

Market Segmentation:

By Type

  • Non-invasive
  • Minimally-invasive
  • Invasive

By Product

  • Monitors
  • Disposables

By End-user

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Home Care Settings

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline
  • 1.8. Key benefits to the stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. Analyst View

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. HEMODYNAMIC MONITORING SYSTEMS MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Non-invasive
    • 5.2.1. Market opportunities and trends
    • 5.2.2. Growth prospects
    • 5.2.3. Geographic lucrativeness
  • 5.3. Minimally-invasive
    • 5.3.1. Market opportunities and trends
    • 5.3.2. Growth prospects
    • 5.3.3. Geographic lucrativeness
  • 5.4. Invasive
    • 5.4.1. Market opportunities and trends
    • 5.4.2. Growth prospects
    • 5.4.3. Geographic lucrativeness

6. HEMODYNAMIC MONITORING SYSTEMS MARKET BY PRODUCT

  • 6.1. Introduction
  • 6.2. Monitors
    • 6.2.1. Market opportunities and trends
    • 6.2.2. Growth prospects
    • 6.2.3. Geographic lucrativeness
  • 6.3. Disposables
    • 6.3.1. Market opportunities and trends
    • 6.3.2. Growth prospects
    • 6.3.3. Geographic lucrativeness

7. HEMODYNAMIC MONITORING SYSTEMS MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals & Clinics
    • 7.2.1. Market opportunities and trends
    • 7.2.2. Growth prospects
    • 7.2.3. Geographic lucrativeness
  • 7.3. Ambulatory Care Centers
    • 7.3.1. Market opportunities and trends
    • 7.3.2. Growth prospects
    • 7.3.3. Geographic lucrativeness
  • 7.4. Home Care Settings
    • 7.4.1. Market opportunities and trends
    • 7.4.2. Growth prospects
    • 7.4.3. Geographic lucrativeness

8. HEMODYNAMIC MONITORING SYSTEMS MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Type
    • 8.2.2. By Product
    • 8.2.3. By End-user
    • 8.2.4. By Country
      • 8.2.4.1. United States
        • 8.2.4.1.1. Market Trends and Opportunities
        • 8.2.4.1.2. Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1. Market Trends and Opportunities
        • 8.2.4.2.2. Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1. Market Trends and Opportunities
        • 8.2.4.3.2. Growth Prospects
  • 8.3. South America
    • 8.3.1. By Type
    • 8.3.2. By Product
    • 8.3.3. By End-user
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1. Market Trends and Opportunities
        • 8.3.4.1.2. Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1. Market Trends and Opportunities
        • 8.3.4.2.2. Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1. Market Trends and Opportunities
        • 8.3.4.3.2. Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Type
    • 8.4.2. By Product
    • 8.4.3. By End-user
    • 8.4.4. By Country
      • 8.4.4.1. Germany
        • 8.4.4.1.1. Market Trends and Opportunities
        • 8.4.4.1.2. Growth Prospects
      • 8.4.4.2. France
        • 8.4.4.2.1. Market Trends and Opportunities
        • 8.4.4.2.2. Growth Prospects
      • 8.4.4.3. United Kingdom
        • 8.4.4.3.1. Market Trends and Opportunities
        • 8.4.4.3.2. Growth Prospects
      • 8.4.4.4. Italy
        • 8.4.4.4.1. Market Trends and Opportunities
        • 8.4.4.4.2. Growth Prospects
      • 8.4.4.5. Spain
        • 8.4.4.5.1. Market Trends and Opportunities
        • 8.4.4.5.2. Growth Prospects
      • 8.4.4.6. Others
        • 8.4.4.6.1. Market Trends and Opportunities
        • 8.4.4.6.2. Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Type
    • 8.5.2. By Product
    • 8.5.3. By End-user
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
        • 8.5.4.1.1. Market Trends and Opportunities
        • 8.5.4.1.2. Growth Prospects
      • 8.5.4.2. UAE
        • 8.5.4.2.1. Market Trends and Opportunities
        • 8.5.4.2.2. Growth Prospects
      • 8.5.4.3. Others
        • 8.5.4.3.1. Market Trends and Opportunities
        • 8.5.4.3.2. Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Type
    • 8.6.2. By Product
    • 8.6.3. By End-user
    • 8.6.4. By Country
      • 8.6.4.1. China
        • 8.6.4.1.1. Market Trends and Opportunities
        • 8.6.4.1.2. Growth Prospects
      • 8.6.4.2. India
        • 8.6.4.2.1. Market Trends and Opportunities
        • 8.6.4.2.2. Growth Prospects
      • 8.6.4.3. Japan
        • 8.6.4.3.1. Market Trends and Opportunities
        • 8.6.4.3.2. Growth Prospects
      • 8.6.4.4. South Korea
        • 8.6.4.4.1. Market Trends and Opportunities
        • 8.6.4.4.2. Growth Prospects
      • 8.6.4.5. Taiwan
        • 8.6.4.5.1. Market Trends and Opportunities
        • 8.6.4.5.2. Growth Prospects
      • 8.6.4.6. Thailand
        • 8.6.4.6.1. Market Trends and Opportunities
        • 8.6.4.6.2. Growth Prospects
      • 8.6.4.7. Indonesia
        • 8.6.4.7.1. Market Trends and Opportunities
        • 8.6.4.7.2. Growth Prospects
      • 8.6.4.8. Others
        • 8.6.4.8.1. Market Trends and Opportunities
        • 8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisition, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Edward Lifesciences Corporation
  • 10.2. GE Healthcare
  • 10.3. Koninklijke Philips N.V.
  • 10.4. Draeger
  • 10.5. LiDCO Group PLC
  • 10.6. Pulsion Medical Systems SE
  • 10.7. ICU Medical, Inc.
  • 10.8. Cheetah Medical, Inc.
  • 10.9. CNSystems Medizintechnik GmbH
  • 10.10. Schwarzer Cardiotek GmbH